MTOR and cancer: Following the discovery of its target, the mTOR complex, rapamycin (or sirolimus), and its analogs (everolimus, temsirolimus) became therapeutic options for patients with various types of cancer (e.g., breast, kidney, or central nervous system tumors), but clinical results have been highly variable.